CD19 and acute lymphoblastic leukemia: Based on extensive literature data, this study quantitatively compared the efficacy and safety of anti-CD19 CAR T-cell therapy including the 4-1BB and CD28 co-stimulatory domains in the treatment of B-ALL for the first time.